Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected cambodian patients

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 10, 2010, Pages 4432-4439

  Chou, Monidarin ^a   Bertrand, Julie ^b   Segeral, Olivier ^c   Verstuyft, Céline ^c,d   Borand, Laurence ^e   Comets, Emmanuelle ^b   Le Tiec, Clotilde ^c   Becquemont, Laurent ^c,d   Ouk, Vara ^f   Mentre, France ^b   Taburet, Anne Marie ^c  

^a UNIVERSITY OF HEALTH SCIENCES   (Cambodia)

^b INSERM   (France)

^c BICÊTRE HOSPITAL   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

^f Hopital Calmette   (Cambodia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOCHROME P450 2B6; LAMIVUDINE; MULTIDRUG RESISTANCE PROTEIN 1; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADD ON THERAPY; ADULT; ALLELE; ARTICLE; CAMBODIA; CREATININE CLEARANCE; DRUG SUBSTITUTION; ENVIRONMENTAL FACTOR; EXPOSURE; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HEREDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE DRUG DOSE; PHARMACOGENETICS; POPULATION MODEL; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; YOUNG ADULT;

EID: 77957347128     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00512-10     Document Type: Article

References (51)

1. Almond, L. M., D. Edirisinghe, M. Dalton, A. Bonington, D. J. Back, and S. H. Khoo. 2005. Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clin. Pharmacol. Ther. 78:132-142.
2. Amico, K. R., W. A. Fisher, D. H. Cornman, P. A. Shuper, C. G. Redding, D. J. Konkle-Parker, W. Barta, and J. D. Fisher. 2006. Visual analog scale of ART adherence: association with 3-day self-report and adherence barriers. J. Acquir. Immune Defic. Syndr. 42:455-459.
3. Anderson, P. L., C. L. Aquilante, E. M. Gardner, J. Predhomme, P. McDaneld, L. R. Bushman, J. H. Zheng, M. Ray, and S. MaWhinney. 2009. Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. J. Antimicrob. Chemother. 64:1071-1079.
4. Balram, C., A. Sharma, C. Sivathasan, and E. J. Lee. 2003. Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. Br. J. Clin. Pharmacol. 56:78-83.
5. Bertrand, J., E. Comets, C. M. Laffont, M. Chenel, and F. Mentre. 2009. Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm. J. Pharmacokinet. Pharmacodyn. 36:317-339.
6. Bertrand, J., E. Comets, and F. Mentre. 2008. Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters. J. Biopharm. Stat. 18:1084-1102.
7. Calmy, A., L. Pinoges, E. Szumilin, R. Zachariah, N. Ford, and L. Ferradini. 2006. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 20:1163-1169. (Pubitemid 43786105)
8. Cammett, A. M., T. R. MacGregor, J. M. Wruck, F. Felizarta, P. Miailhes, J. Mallolas, and P. J. Piliero. 2009. Pharmacokinetic assessment of nevirapine and metabolites in human immunodeficiency virus type 1-infected patients with hepatic fibrosis. Antimicrob. Agents Chemother. 53:4147-4152.
9. Chantarangsu, S., T. R. Cressey, S. Mahasirimongkol, E. Capparelli, Y. Tawon, N. Ngo-Giang-Huong, G. Jourdain, M. Lallemant, and W. Chantratita. 2009. Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women. J. Antimicrob. Chemother. 64:1265-1273.
10. Chou, M., J. Bertrand, O. Segeral, C. Verstuyft, L. Borand, E. Comets, L. Becquemont, V. Ouk, F. Mentré, Anne-Marie Taburet, and the ANRS 12154 Study Group. 2009. Inter- and intra-patient variability in nevirapine plasma concentrations in HIV-infected Cambodian patients and the effect of CYP2B6 genetic polymorphism: ANRS 12154 study, abstr. 691. 16th Conf. Retrovir. Opportunistic Infect., Montreal, Quebec, Canada, 8 to 11 February 2009.
11. Coulbault, L., M. Beaussier, C. Verstuyft, H. Weickmans, L. Dubert, D. Tregouet, C. Descot, Y. Parc, A. Lienhart, P. Jaillon, and L. Becquemont. 2006. Environmental and genetic factors associated with morphine response in the postoperative period. Clin. Pharmacol. Ther. 79:316-324.
12. Dailly, E., E. Billaud, V. Reliquet, S. Breurec, P. Perre, S. Leautez, P. Jolliet, M. Bourin, and F. Raffi. 2004. No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors. Eur. J. Clin. Pharmacol. 60:343-348.
13. de Maat, M. M., A. D. Huitema, J. W. Mulder, P. L. Meenhorst, E. C. van Gorp, and J. H. Beijnen. 2002. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br. J. Clin. Pharmacol. 54:378-385.
14. Elsherbiny, D., K. Cohen, B. Jansson, P. Smith, H. McIlleron, and U. S. Simonsson. 2009. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. Eur. J. Clin. Pharmacol. 65:71-80.
15. Erickson, D. A., G. Mather, W. F. Trager, R. H. Levy, and J. J. Keirns. 1999. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab. Dispos. 27:1488-1495.
16. Estrela, R. C., A. B. Santoro, P. F. Barroso, M. Tuyama, and G. Suarez-Kurtz. 2008. CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects. Clin. Pharmacol. Ther. 84:205-207.
17. Ferradini, L., D. Laureillard, N. Prak, C. Ngeth, M. Fernandez, L. Pinoges, G. Puertas, A. M. Taburet, N. Ly, C. Rouzioux, S. Balkan, C. Quillet, and J. F. Delfraissy. 2007. Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS 21:2293-2301.
18. Gandhi, M., L. Z. Benet, P. Bacchetti, A. Kalinowski, K. Anastos, A. R. Wolfe, M. Young, M. Cohen, H. Minkoff, S. J. Gange, and R. M. Greenblatt. 2009. Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women. J. Acquir. Immune Defic. Syndr. 50:482-491.
19. Gatanaga, H., T. Hayashida, K. Tsuchiya, M. Yoshino, T. Kuwahara, H. Tsukada, K. Fujimoto, I. Sato, M. Ueda, M. Horiba, M. Hamaguchi, M. Yamamoto, N. Takata, A. Kimura, T. Koike, F. Gejyo, S. Matsushita, T. Shirasaka, S. Kimura, and S. Oka. 2007. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin. Infect. Dis. 45:1230-1237.
20. Goujard, C., M. Legrand, X. Panhard, B. Diquet, X. Duval, G. Peytavin, I. Vincent, C. Katlama, C. Leport, B. Bonnet, D. Salmon-Ceron, F. Mentre, and A. M. Taburet. 2005. High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy. Clin. Pharmacokinet. 44:1267-1278.
21. Guan, S., M. Huang, X. Li, X. Chen, E. Chan, and S. F. Zhou. 2006. Intra- and inter-ethnic differences in the allele frequencies of cytochrome P450 2B6 gene in Chinese. Pharm. Res. 23:1983-1990.
22. Haas, D. W., T. Gebretsadik, G. Mayo, U. N. Menon, E. P. Acosta, A. Shintani, M. Floyd, C. M. Stein, and G. R. Wilkinson. 2009. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans. J. Infect. Dis. 199:872-880.
23. Haas, D. W., H. J. Ribaudo, R. B. Kim, C. Tierney, G. R. Wilkinson, R. M. Gulick, D. B. Clifford, T. Hulgan, C. Marzolini, and E. P. Acosta. 2004. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18:2391-2400.
24. Hiratsuka, M., Y. Takekuma, N. Endo, K. Narahara, S. I. Hamdy, Y. Kishikawa, M. Matsuura, Y. Agatsuma, T. Inoue, and M. Mizugaki. 2002. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur. J. Clin. Pharmacol. 58:417-421.
25. Josephson, F., A. Allqvist, M. Janabi, J. Sayi, E. Aklillu, M. Jande, M. Mahindi, J. Burhenne, Y. Bottiger, L. L. Gustafsson, W. E. Haefeli, and L. Bertilsson. 2007. CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clin. Pharmacol. Ther. 81:708-712.
26. Klein, K., T. Lang, T. Saussele, E. Barbosa-Sicard, W. H. Schunck, M. Eichelbaum, M. Schwab, and U. M. Zanger. 2005. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet. Genomics 15:861-873.
27. Lamson, M. J., J. P. Sabo, T. R. MacGregor, J. W. Pav, L. Rowland, A. Hawi, M. Cappola, and P. Robinson. 1999. Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharm. Drug Dispos. 20:285-291.
28. Laurent, C., C. Kouanfack, S. Koulla-Shiro, N. Nkoue, A. Bourgeois, A. Calmy, B. Lactuock, V. Nzeusseu, R. Mougnutou, G. Peytavin, F. Liegeois, E. Nerrienet, M. Tardy, M. Peeters, I. Andrieux-Meyer, L. Zekeng, M. Kazatchkine, E. Mpoudi-Ngole, and E. Delaporte. 2004. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 364:29-34. (Pubitemid 38968622)
29. Mahungu, T., C. Smith, F. Turner, D. Egan, M. Youle, M. Johnson, S. Khoo, D. Back, and A. Owen. 2009. Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med. 10:310-317.
30. Makeeva, O., V. Stepanov, V. Puzyrev, D. B. Goldstein, and I. Grossman. 2008. Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes. Pharmacogenomics 9:847-868.
31. Manosuthi, W., S. Sungkanuparph, P. Tantanathip, A. Lueangniyomkul, W. Mankatitham, W. Prasithsirskul, S. Burapatarawong, S. Thongyen, S. Likanonsakul, U. Thawornwa, V. Prommool, and K. Ruxrungtham. 2009. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R study. Clin. Infect. Dis. 48:1752-1759.
32. Marier, J. F., M. Dimarco, R. Guilbaud, C. Dodard, G. Morelli, S. K. Tippabhotla, A. K. Singla, N. R. Thudi, and T. Monif. 2007. Pharmacokinetics of lamivudine, zidovudine, and nevirapine administered as a fixed-dose combination formulation versus coadministration of the individual products. J. Clin. Pharmacol. 47:1381-1389.
33. Mehlotra, R. K., M. N. Ziats, M. J. Bockarie, and P. A. Zimmerman. 2006. Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur. J. Clin. Pharmacol. 62:267-275.
34. Molto, J., M. Valle, C. Miranda, S. Cedeno, J. Miranda, J. R. Santos, E. Negredo, J. Vilaro, J. Costa, and B. Clotet. 2008. Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach. J. Antimicrob. Chemother. 62:784-792.
35. Nettles, R. E., T. L. Kieffer, T. Parsons, J. Johnson, J. Cofrancesco, Jr., J. E. Gallant, K. A. Carson, R. F. Siliciano, and C. Flexner. 2006. Marked intra-individual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin. Infect. Dis. 42:1189-1196.
36. Ozdemir, V., W. Kalow, B. K. Tang, A. D. Paterson, S. E. Walker, L. Endrenyi, and A. D. Kashuba. 2000. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10:373-388.
37. Penzak, S. R., G. Kabuye, P. Mugyenyi, F. Mbamanya, V. Natarajan, R. M. Alfaro, C. Kityo, E. Formentini, and H. Masur. 2007. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med. 8:86-91.
38. Pinheiro, J. C., and D. M. Bates. 2000. Mixed-effects models in S and S-PLUS, 1st ed. Springer-Verlag, New York, NY.
39. Puthanakit, T., P. Tanpaiboon, L. Aurpibul, T. R. Cressey, and V. Sirisanthana. 2009. Plasma efavirenz concentrations and the association with CYP2B6-516G>T polymorphism in HIV-infected Thai children. Antivir. Ther. 14:315-320.
40. Quteineh, L., C. Verstuyft, V. Furlan, A. Durrbach, A. Letierce, S. Ferlicot, A. M. Taburet, B. Charpentier, and L. Becquemont. 2008. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin. Pharmacol. Toxicol. 103:546-552.
41. Rotger, M., S. Colombo, H. Furrer, G. Bleiber, T. Buclin, B. L. Lee, O. Keiser, J. Biollaz, L. Decosterd, and A. Telenti. 2005. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet. Genomics 15:1-5. (Pubitemid 43205520)
42. Rouet, F., M. L. Chaix, E. Nerrienet, N. Ngo-Giang-Huong, J. C. Plantier, M. Burgard, M. Peeters, F. Damond, D. K. Ekouevi, P. Msellati, L. Ferradini, S. Rukobo, V. Marechal, N. Schvachsa, L. Wakrim, C. Rafalimanana, B. Rakotoambinina, J. P. Viard, J. M. Seigneurin, and C. Rouzioux. 2007. Impact of HIV-1 genetic diversity on plasma HIV-1 RNA quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J. Acquir. Immune Defic. Syndr. 45:380-388.
43. Sabo, J. P., M. J. Lamson, G. Leitz, C. L. Yong, and T. R. MacGregor. 2000. Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection. AAPS PharmSci. 2:E1.
44. Saitoh, A., E. Sarles, E. Capparelli, F. Aweeka, A. Kovacs, S. K. Burchett, A. Wiznia, S. Nachman, T. Fenton, and S. A. Spector. 2007. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 21:2191-2199.
45. Solas, C., N. Simon, M. P. Drogoul, S. Quaranta, V. Frixon-Marin, V. Bourgarel-Rey, C. Brunet, J. A. Gastaut, A. Durand, B. Lacarelle, and I. Poizot-Martin. 2007. Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients. Br. J. Clin. Pharmacol. 64:353-362.
46. Spire, B., P. Carrieri, P. Sopha, C. Protopopescu, N. Prak, C. Quillet, C. Ngeth, L. Ferradini, J. F. Delfraissy, and D. Laureillard. 2008. Adherence to antiretroviral therapy in patients enrolled in a comprehensive care program in Cambodia: a 24-month follow-up assessment. Antivir. Ther. 13:697-703.
47. Telenti, A., and U. M. Zanger. 2008. Pharmacogenetics of anti-HIV drugs. Annu. Rev. Pharmacol. Toxicol. 48:227-256.
48. Tian, C., R. Kosoy, A. Lee, M. Ransom, J. W. Belmont, P. K. Gregersen, and M. F. Seldin. 2008. Analysis of East Asia genetic substructure using genome-wide SNP arrays. PLoS One 3:e3862.
49. Titier, K., F. Lagrange, F. Pehourcq, L. Edno-Mcheik, N. Moore, and M. Molimard. 2002. High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma. Ther. Drug Monit. 24:417-424.
50. Veiga, M. I., S. Asimus, P. E. Ferreira, J. P. Martins, I. Cavaco, V. Ribeiro, T. N. Hai, M. G. Petzold, A. Bjorkman, M. Ashton, and J. P. Gil. 2009. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. Eur. J. Clin. Pharmacol. 65:355-363.
51. Zhou, X.-J., L. B. Sheiner, R. T. D'Aquila, M. D. Hughes, M. S. Hirsch, M. A. Fischl, V. A. Johnson, M. Myers, J.-P. Sommadossi, and the National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. 1999. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 43:121-128.